Regional variation in prevalence of difficult-to-treat asthma and oral corticosteroid use for patients in Australia: heat map analysis

References

• Chung KF, Wenzel SE, Brozek JL, Bush A, Castro M, Sterk PJ, Adcock IM, Bateman ED, Bel EH, Bleecker ER, et al. International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma. Eur Respir J. 2014;43(2):343–373. doi:10.1183/09031936.00202013.
   PubMed Web of Science ®Google Scholar
• GBD 2016 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet. 2017;390(10100):1211–1259.
   PubMed Web of Science ®Google Scholar
• Chastek B, Korrer S, Nagar SP, Albers F, Yancey S, Ortega H, Forshag M, Dalal AA. Economic burden of illness among patients with severe asthma in a managed care setting. JMCP. 2016;22(7):848–861. doi:10.18553/jmcp.2016.22.7.848.
   PubMedGoogle Scholar
• Zeiger RS, Schatz M, Dalal AA, Qian L, Chen W, Ngor EW, Suruki RY, Kawatkar AA. Utilization and costs of severe uncontrolled asthma in a managed-care setting. J Allergy Clin Immunol Pract. 2016;4(1):120–129 e3. doi:10.1016/j.jaip.2015.08.003.
   PubMed Web of Science ®Google Scholar
• Hankin CS, Bronstone A, Wang Z, Small MB, Buck P. Estimated prevalence and economic burden of severe, uncontrolled asthma in the United States. J Allergy Clin Immunol. 2013;131(2):AB126. doi:10.1016/j.jaci.2012.12.1118.
   Web of Science ®Google Scholar
• Hekking P-PW, Wener RR, Amelink M, Zwinderman AH, Bouvy ML, Bel EH. The prevalence of severe refractory asthma. J Allergy Clin Immunol. 2015;135(4):896–902. doi:10.1016/j.jaci.2014.08.042.
   PubMed Web of Science ®Google Scholar
• Chen S, Golam S, Myers J, Bly C, Smolen H, Xu X. Systematic literature review of the clinical, humanistic, and economic burden associated with asthma uncontrolled by GINA Steps 4 or 5 treatment. Curr Med Res Opin. 2018;34(12):2075–2088. doi:10.1080/03007995.2018.1505352.
   PubMed Web of Science ®Google Scholar
• Australian Bureau of Statistics. 4364.0.55.001 - National Health Survey: First Results, 2017-18: Chronic Conditions. Canberra: Australian Bureau of Statistics; 2018 [cited 2020 28 October]. Available from: https://www.abs.gov.au/ausstats/[email protected]/mf/4364.0.55.001.
   Google Scholar
• Global Asthma Network. The Global Asthma Report 2018 Auckland. New Zealand: Global Asthma Network; 2018. [cited 2020 14 August]. Available from: http://www.globalasthmareport.org/resources/global_asthma_report_2018.pdf.
   Google Scholar
• Australian Bureau of Statistics. 4364.0.55.001 - National Health Survey: First Results, 2017-18: Data downloads: Table 2.3. Canberra: Australian Bureau of Statistics; 2018 [cited 2020 28 October]. Available from: https://www.abs.gov.au/statistics/health/health-conditions-and-risks/national-health-survey-first-results/latest-release#data-download.
   Google Scholar
• Reddel HK, Sawyer SM, Everett PW, Flood PV, Peters MJ. Asthma control in Australia: a cross-sectional web-based survey in a nationally representative population. Med J Aust. 2015;202(9):492–497. doi:10.5694/mja14.01564.
   PubMed Web of Science ®Google Scholar
• Global Initiative for Asthma (GINA). Global strategy for asthma management and prevention (2021 update) 2021 [cited 2021 May]. Available from: https://ginasthma.org/wp-content/uploads/2021/04/GINA-2021-Main-Report_FINAL_21_04_28-WMS.pdf.
   Google Scholar
• National Asthma Education Prevention Program Expert Panel Report 3 (EPR-3): guidelines for the diagnosis and management of asthma-summary report 2007. J Allergy Clin Immunol. 2007;120(5 Suppl):S94.
   PubMed Web of Science ®Google Scholar
• Bleecker ER, Menzies-Gow AN, Price DB, Bourdin A, Sweet S, Martin AL, Alacqua M, Tran TN. Systematic Literature Review of Systemic Corticosteroid Use for Asthma Management. Am J Respir Crit Care Med. 2020;201(3):276–293. doi:10.1164/rccm.201904-0903SO.
   PubMed Web of Science ®Google Scholar
• Price DB, Trudo F, Voorham J, Xu X, Kerkhof M, Ling Zhi Jie J, Tran TN. Adverse outcomes from initiation of systemic corticosteroids for asthma: long-term observational study. JAA. 2018;11:193–204. doi:10.2147/JAA.S176026.
   Web of Science ®Google Scholar
• Volmer T, Effenberger T, Trautner C, Buhl R. Consequences of long-term oral corticosteroid therapy and its side-effects in severe asthma in adults: a focused review of the impact data in the literature. Eur Respir J. 2018;52(4):1800703. doi:10.1183/13993003.00703-2018.
   PubMed Web of Science ®Google Scholar
• Reddel HK, Beckert L, Moran A, Ingham T, Ampon RD, Peters MJ, Sawyer SM. Is higher population-level use of ICS/LABA combination associated with better asthma outcomes? Cross-sectional surveys of nationally representative populations in New Zealand and Australia. Respirology. 2017;22(8):1570–1578. doi:10.1111/resp.13123.
   PubMed Web of Science ®Google Scholar
• Hew M, McDonald VM, Bardin PG, Chung LP, Farah CS, Barnard A, Cooper MS, Gibson PG, Upham JW. Cumulative dispensing of high oral corticosteroid doses for treating asthma in Australia. Med J Aust. 2020;213(7):316–320. doi:10.5694/mja2.50758.
   PubMed Web of Science ®Google Scholar
• Haughney J, Winders TA, Holmes S, Chanez P, Saul H, Menzies-Gow A, PRECISION Improve Access to Better Care Task Force. Global Quality Standard for Identification and Management of Severe Asthma. Adv Ther. 2020;37(9):3645–3659. doi:10.1007/s12325-020-01450-7.
   PubMed Web of Science ®Google Scholar
• Chapman KR, Remtulla A, Gendron A, Xu S, Nan C. Regional variation in asthma prevalence and oral corticosteroid use for Canadian patients: heat map analysis. Am J Respir Crit Care Med. 2020;201:A1835–A1835. doi:10.1164/ajrccm-conference.2020.201.1_MeetingAbstracts.A1835.
   Web of Science ®Google Scholar
• Menzies-Gow A, Haslam T, Morris T, et al. P144 Regional variation in OCS use for UK patients with asthma: heat map analysis. Thorax. 2019;74(Suppl 2):A169–A169.
   Google Scholar
• Tran TN, King E, Sarkar R, Nan C, Rubino A, O’Leary C, Muzwidzwa R, Belton L, Quint JK. Oral corticosteroid prescription patterns for asthma in France, Germany, Italy and the UK. Eur Respir J. 2020;55(6):1902363. doi:10.1183/13993003.02363-2019.
   PubMed Web of Science ®Google Scholar
• Australian Bureau of Statistics. 1270.0.55.001 - Australian Statistical Geography Standard (ASGS): Volume 1 - Main Structure and Greater Capital City Statistical Areas, July 2016 Canberra: Australian Bureau of Statistics; 2016 [cited 2020 14 August]. Available from: https://www.abs.gov.au/ausstats/[email protected]/Lookup/by%20Subject/1270.0.55.001∼July%202016∼Main%20Features∼Statistical%20Area%20Level%203%20(SA3)∼10015.
   Google Scholar
• Bloechliger M, Reinau D, Spoendlin J, Chang S-C, Kuhlbusch K, Heaney LG, Jick SS, Meier CR. Adverse events profile of oral corticosteroids among asthma patients in the UK: cohort study with a nested case-control analysis. Respir Res. 2018;19(1):75. doi:10.1186/s12931-018-0742-y.
   PubMed Web of Science ®Google Scholar
• Australian Institute of Health and Welfare. Asthma Canberra: Australian Institute of Health and Welfare; 2019 [cited 2020 14 August]. Available from: https://www.aihw.gov.au/reports/chronic-respiratory-conditions/asthma.
   Google Scholar